

Proteolytic Cleavage of Opa1 Stimulates Mitochondrial Inner Membrane Fusion and Couples Fusion to Oxidative Phosphorylation

Prashant Mishra,¹ Valerio Carelli,³ Giovanni Manfredi,⁴ and David C. Chan^{1,2,*}

¹Division of Biology and Biological Engineering

²Howard Hughes Medical Institute

California Institute of Technology, Pasadena, CA 91125, USA

³IRCCS Istituto delle Scienze Neurologiche di Bologna and Department of Biomedical and NeuroMotor Sciences, University of Bologna, Via Altura 3, 40139 Bologna, Italy

⁴Departments of Neurology and Neuroscience, Weill Medical College of Cornell University, 1300 York Avenue, A501, New York, NY 10065, USA

*Correspondence: dchan@caltech.edu

<http://dx.doi.org/10.1016/j.cmet.2014.03.011>

SUMMARY

Mitochondrial fusion is essential for maintenance of mitochondrial function. The mitofusins GTPases control mitochondrial outer membrane fusion, whereas the dynamin-related GTPase Opa1 mediates inner membrane fusion. We show that mitochondrial inner membrane fusion is tuned by the level of oxidative phosphorylation (OXPHOS), whereas outer membrane fusion is insensitive. Consequently, cells from patients with pathogenic mtDNA mutations show a selective defect in mitochondrial inner membrane fusion. In elucidating the molecular mechanism of OXPHOS-stimulated fusion, we uncover that real-time proteolytic processing of Opa1 stimulates mitochondrial inner membrane fusion. OXPHOS-stimulated mitochondrial fusion operates through Yme1L, which cleaves Opa1 more efficiently under high OXPHOS conditions. Engineered cleavage of Opa1 is sufficient to mediate inner membrane fusion, regardless of respiratory state. Proteolytic cleavage therefore stimulates the membrane fusion activity of Opa1, and this feature is exploited to dynamically couple mitochondrial fusion to cellular metabolism.

INTRODUCTION

Within a cell, the mitochondria exist as a population of dynamic organelles that continually interact through fusion and fission (Chan, 2012; Westermann, 2010; Youle and van der Bliek, 2012). These opposing processes underlie mitochondrial dynamics and serve to maintain the quality of the mitochondrial population. Mitochondrial dynamics has important roles in mitochondrial DNA (mtDNA) stability, respiratory capacity, apoptosis, response to cellular stress, and mitophagy. Mitochondrial fusion is therefore likely to be regulated by cellular physiology, but this issue is poorly understood.

Mitochondrial fusion requires coordination of outer membrane (OM) and inner membrane (IM) fusion. OM and IM fusion normally occur in unison in vivo, but can be experimentally uncoupled (Malka et al., 2005; Meeusen et al., 2004, 2006). OM fusion requires the mitofusins Mfn1 and Mfn2, membrane-bound GTPases located on the OM. IM fusion requires the dynamin-related GTPase Opa1 (Meeusen et al., 2006; Song et al., 2009). Each Opa1 splice form (Delettre et al., 2001) encodes an Opa1 precursor that is imported into the mitochondrion, where the N-terminal mitochondrial targeting sequence is removed to produce a long isoform of Opa1 (l-Opa1) embedded in the IM. At steady state, about half of Opa1 exists as l-Opa1, with the remainder cleaved at S1 or S2 sites to create short forms (s-Opa1) that are no longer membrane anchored (Ishihara et al., 2006). The Oma1 protease is required for S1 cleavage, which occurs at basal levels but can be dramatically induced by depolarization of mitochondria (Ehse et al., 2009; Head et al., 2009). The Yme1L protease is involved in cleavage at S2 (Griparic et al., 2007; Song et al., 2007). A combination of long and short Opa1 isoforms is necessary for fusion (DeVay et al., 2009; Herlan et al., 2003; Song et al., 2007).

Cellular bioenergetics affects mitochondrial dynamics, but this relationship is understood only in vague terms and is complicated by conflicting data. Mitochondrial fusion in vitro requires ATP or an energy regenerating system (Hoppins et al., 2011; Meeusen et al., 2004; Schauss et al., 2010), but the basis of this requirement is unclear. Some mammalian cells have been reported to respond to galactose medium by enhancing mitochondria tubulation over a period of 2 weeks (Rossignol et al., 2004), but it is unknown whether this morphology change reflects an increase in fusion or a decrease in fission. Moreover, other cell types appear to have no response (Rossignol et al., 2004). Some mammalian cells with OXPHOS defects contain fragmented mitochondria (Koopman et al., 2005; Kwong et al., 2007; Sauvanet et al., 2010), and yeast cells with defective mtDNA show reduced mitochondrial fusion (Sauvanet et al., 2012). It is unknown whether these changes are direct or indirect consequences of mitochondrial dysfunction. However, there are also well-documented cases of patient cells with OXPHOS defects that have no apparent change in mitochondrial




Figure 1. Oxidative Conditions Stimulate Mitochondrial Fusion

(A) Inducing oxygen consumption with oxidative media. MEFs were grown in glucose-containing media and then switched to glucose-, galactose-, or acetoacetate-containing media. Error bars indicate standard deviations.

(B) Quantitation of mitochondrial morphology at 24 hr after media shift. Cells were classified as having mostly fragmented mitochondria, short tubular mitochondria or long tubular mitochondria. Error bars indicate standard deviations.

(C) Representative images of mitochondrial morphology (matrix-targeted DsRed) at 24 hr after media shift. Scale bar, 5 μ m.

morphology (Guillery et al., 2008a; Handran et al., 1997; Huckriede et al., 1995; Sauvanet et al., 2010). In addition, some mitochondrial fusion does proceed in mammalian or yeast cells entirely lacking mtDNA (ρ^0 cells), indicating that mitochondrial fusion can occur in the absence of OXPHOS (Hermann et al., 1998; Legros et al., 2002). These disparate observations do not suggest a simple relationship between OXPHOS activity and mitochondrial fusion.

To resolve these issues, we studied the dependence of mitochondrial fusion on the respiratory activity of mitochondria in vitro and in vivo. Using an in vitro fusion assay with isolated mitochondria, we find that OXPHOS stimulates the coupling between OM and IM fusion. This regulatory mechanism extends to live cells, and patient cells with mtDNA mutations show a selective defect in IM fusion. In the course of identifying the molecular basis for this regulation, we discovered that ongoing cleavage of l-Opa1 stimulates IM fusion. OXPHOS upregulates IM fusion by enhancing Opa1 cleavage by Yme1L. Indeed, by artificially activating Opa1 cleavage, we can trigger IM fusion in vitro. These results indicate that dynamin-related proteins can be activated for membrane fusion by proteolysis and provide a molecular link between cellular metabolism and mitochondrial fusion.

RESULTS

Oxidative Culture Conditions Promote Mitochondrial Elongation

Given the central role of mitochondria in energy production, we speculated that mitochondrial dynamics might be responsive

to cellular metabolism. We used 96-well oxygen consumption measurements to identify specialized media formulations that robustly affect the respiratory activity of mitochondria in cultured mouse embryonic fibroblasts (MEFs). Starting with pyruvate-lacking media with a moderate concentration (10 mM) of glucose, we found that a switch to media containing galactose or ketone bodies (acetoacetate) as the carbon source results in a 1.5- to 2-fold increase in mitochondrial respiration within 30 min (Figure 1A). At

this early time, there are no changes in mitochondrial morphology, but by 24 hr a dramatic restructuring is apparent. Whereas cells maintained in customized glycolytic (glucose-containing) media show mostly fragmented and short tubular mitochondria, cells shifted to oxidative media (galactose or acetoacetate) display an increase in long tubular mitochondria (Figures 1B and 1C). Conversely, shifting cells from glucose-free media to glycolytic media results in a rapid reduction in respiratory activity that is accompanied by a dramatic shortening of mitochondrial length over 24 hr (Figures S1A–S1C). *Mfn1* null cells show an increase in respiration in oxidative media but do not elongate their mitochondria (Figures S1D–S1F), indicating that the rise in respiration is a primary response that is not due to a morphology change. The elongation is not associated with changes in the levels of fusion and fission machinery components (Figure S1G), nor mitochondrial accumulation or phosphorylation of Drp1 (a key component of the fission machinery), mechanisms previously shown (Cereghetti et al., 2008; Cribbs and Strack, 2007) to regulate fission (Figures S1H and S1I).

IM Fusion In Vitro Is Tuned by OXPHOS Activity

To directly probe the relationship between OXPHOS and mitochondrial fusion, we turned to an in vitro fusion assay involving isolated organelles (Figure 2A). Mitochondrial fusion is a multi-step process consisting of OM fusion followed by IM fusion (Meeusen et al., 2004). We developed an in vitro fusion assay with a fluorescent readout that allows these steps to be resolved. Mitochondria were separately isolated from two cell lines stably expressing fluorescent submitochondrial markers. One cell line




Figure 2. OXPHOS Stimulates Inner Membrane Fusion In Vitro

(A) Schematic of the in vitro fusion assay. Mitochondria containing OM-targeted GFP and matrix CFP were mixed with mitochondria containing matrix RFP. Full fusion events (both OM and IM fusion) are indicated by colocalized CFP and RFP matrices that are surrounded by a single GFP membrane. OM fusion intermediates are indicated by apposed but distinct CFP and RFP matrices that are surrounded by a single GFP membrane.

(B) Image of an in vitro fusion reaction showing unfused mitochondria, OM fusion intermediates (arrow), and full fusion events (arrowhead). Scale bar, 1 μ m.

(C) Dependence of OM and IM in vitro fusion events on respiratory substrates. Events are plotted as percentage of total mitochondria.

(D) Sensitivity of in vitro fusion to ETC inhibition in respiratory conditions. ADP and GTP are present in all reactions. Pyruvate, malate ("Pyr/Mal," complex I substrates), or succinate (complex II substrate) was added as indicated. The following drugs were tested: rotenone (complex I inhibitor), atpenin A5 (AA5, complex II inhibitor), antimycin A (Ant A, complex III inhibitor), potassium cyanide (KCN, complex IV inhibitor), and oligomycin (oligo, complex V inhibitor). Same color schemes as (C).

(E) Partial support of in vitro fusion events by ATP or the tricarboxylic acid cycle. Same color scheme as (C). GTP and ATP were added as indicated. TCA: substrates for the tricarboxylic acid cycle (α -ketoglutarate, aspartate, NADH).

(F) OM (top) and IM (bottom) fusion rates in vitro as a function of oxygen consumption rate. All error bars indicate standard deviations.

expressed GFP targeted to the OM membrane and CFP targeted to the matrix; the other expressed RFP targeted to the matrix. This combination of markers allows facile scoring of both OM and IM fusion events simultaneously in a single reaction after mixing (Figures 2B and S2A). Full fusion events are defined by coupled OM and IM fusion and result in complete colocalization of CFP and RFP fluorescence, which are surrounded by a single GFP-labeled membrane (Figure S2B). OM events that do not progress to IM fusion result in neighboring CFP and RFP compartments that are surrounded by a single GFP-labeled OM (Figure S2C). With optimal reaction conditions (see later), greater than 20% of the mitochondria show full fusion, with very few intermediates trapped at the initial stage of OM fusion (Figure 2C). This fusion assay shows several expected features: OM fusion depends on both GTP hydrolysis and mitofusins, whereas IM fusion requires Opa1 (Figures S2D and S2E).

We found that efficient coupling of OM and IM fusion requires the presence of respiratory substrates such as succinate and ADP for respiration via complex II of the electron transport chain (ETC) (Figure 2C). When both substrate and ADP are supplied, > 95% of OM fusion events culminate in IM fusion. These condi-

tions correspond to state 3 respiration (Chance and Williams, 1955), where substrate and ADP are not limiting, and the ETC is highly active. In contrast, when both succinate and ADP are absent, OM fusion proceeds at normal levels but is completely uncoupled from IM fusion (Figure 2C). When only ADP or succinate is omitted, about half of the OM fusion events progress to full fusion. This effect is probably due to low levels of endogenous ADP and substrate present in the mitochondrial preparations. Consistent with this idea, preincubation of mitochondria with ADP to deplete endogenous substrate abolishes this effect (Figure S2F).

These reconstitution data suggest that OXPHOS rates can control mitochondrial fusion efficiency at the level of IM fusion. Oxygen consumption measurements indicated that our isolated mitochondria are highly active, intact, and responsive to pharmacologic inhibition of the ETC (Figures S2G and S2H). We therefore tested the effect of OXPHOS inhibition on OM and IM fusion. With the complex II substrate succinate, inhibition of ETC complex II, III, IV, or the ATP synthase (complex V) potently blocks IM fusion but leaves OM fusion intact (Figure 2D). The inhibitory effect of the complex II inhibitor atpenin A5 can be




Figure 3. Inner Membrane Fusion Is Inhibited under Glycolytic Conditions In Vivo

(A) OM fusion in wild-type MEFs. At time $t = 0$ min, PA-GFP in the OM was activated in a region of interest (red box). Dilution of the PA-GFP signal was followed every 3 min for 30 min. Representative images at 0 min and 30 min are shown. Scale bar, 5 μ m. (B) IM fusion in wild-type MEFs. Same as in (A), but using PA-GFP targeted to the matrix. Scale bar, 5 μ m.

(C) OM and IM fusion rates in vivo in glycolytic and oxidative media, measured by dilution of PA-GFP. The p values were calculated for the slopes (pixel intensity versus time) using the Student's t test.

(D) OM and IM fusion rates in vivo in the presence and absence of the complex III inhibitor antimycin A (Ant A). As a negative control, data from mitofusin-deficient MEFs (*Mfn*: *Mfn1*^{-/-}, *Mfn2*^{-/-}) are shown. The p values were calculated as in (C). All error bars indicate standard deviations. *p < 0.01.

The ultimate function of the ETC is to drive formation of ATP in the mitochondrial matrix via complex V activity. When ATP is added to the fusion reaction in the absence of respiratory substrates, we obtained a partial rescue of IM fusion (Figure 2E). This effect was not due to a stimulation of OXPHOS, via contaminating ATPases that may generate ADP (Figure S2L). Similarly, production of ATP via induction of substrate level phosphorylation in the tricarboxylic acid (TCA) cycle partially rescues IM fusion in the absence of respiratory substrates (Figure 2E).

bypassed by driving the ETC via complex I with pyruvate and malate. Analogously, the complex I inhibitor rotenone potentially blocks IM fusion driven by complex I substrates (pyruvate/malate) but does not inhibit fusion driven by succinate. In contrast, OM fusion occurs at normal levels in mitochondria with impaired OXPHOS.

We tested whether inactivation of Opa1 via enhanced processing might be responsible for the sensitivity of IM fusion to respiration inhibition. Loss of membrane potential through the addition of uncouplers (e.g., CCCP) causes inactivation of Opa1 via complete cleavage of the long form (Duvézin-Caubet et al., 2006; Ishihara et al., 2006) by the protease Oma1 (Ehse et al., 2009; Head et al., 2009). In our in vitro fusion reactions, CCCP induced efficient cleavage of Opa1 to short isoforms as expected (Figure S2I). In contrast, pharmacologic inhibition of OXPHOS or the lack of respiratory substrates did not cause such aberrant Opa1 processing (Figures S2I and S2J). Thus, the sensitivity of IM fusion to respiration is not a consequence of proteolytic inactivation of Opa1. In addition, mitochondrial membrane potential does not appear to be the key factor, because oligomycin treatment results in loss of IM fusion despite hyperpolarization of the mitochondria (Figure S2K).

Taken together, these data reveal two important features of mitochondrial fusion in vitro. First, OM fusion is highly active as long as mitofusins and GTP are present. Second, ETC activity can stimulate mitochondrial IM fusion in vitro. To extend this latter concept, we tested whether the activity of the ETC might directly tune the levels of mitochondrial fusion. By systematically varying the availability of respiratory substrates in vitro, we found that the IM fusion rate closely correlates with oxygen consumption, whereas OM fusion is insensitive (Figures 2F and S2M).

IM Fusion in Cultured Cells Can Be Controlled by OXPHOS Activity

To test whether these in vitro insights apply to intact cells, we measured mitochondrial fusion in cells as a function of respiration. Utilizing a photoactivatable GFP (PA-GFP) targeted to either the OM or matrix, we measured OM and IM fusion rates, respectively, by following the decline in PA-GFP intensity due to fusion (Figure 3). Consistent with our in vitro results, OM fusion rates are statistically indistinguishable in glycolytic versus oxidative media, whereas IM fusion rates increase in oxidative media (Figures 3A–3C). This increase in IM fusion is apparent at 1–2 hr after the media shift, well before any obvious change in the steady-state morphology of mitochondria. Similarly, inhibition of




Figure 4. Pathogenic mtDNA Mutations Impair OXPHOS-Driven IM Fusion

(A) Failure of ND1 (complex I mutant) and COX1 (complex IV mutant) cells to elongate mitochondria when shifted to oxidative media for 4 hr. Mitochondria were visualized via expression of matrix-targeted DsRed. Scale bar, 5 μ m.

(B) Quantification of mitochondrial morphology in wild-type and mutant cells in glycolytic (“Glucose”) versus oxidative (“Acetoacetate”) media.

(C) Defective IM fusion in vitro in mitochondria of mutant cells. All reactions contain GTP. Pyr, pyruvate; Mal, malate; Suc, succinate; TCA, substrates for the tricarboxylic acid cycle (α -ketoglutarate, aspartate, NADH). All error bars indicate standard deviations.

OXPHOS by the complex III inhibitor antimycin A causes a prominent decrease in IM fusion efficiency with no observable effect on OM fusion (Figure 3D).

By tracking individually labeled mitochondria, we could directly visualize the coupling of OM and IM fusion (Figure S3). In customized glycolytic media, 38% of OM fusion events did not immediately proceed to IM fusion (28 of 74). In contrast, in oxidative media, only 7% of OM fusion events (5 of 70) did not proceed to IM fusion. Thus, OXPHOS activity has a selective effect on the IM fusion efficiency. Under glycolytic conditions, many OM fusion events are uncoupled from IM fusion. These events were subsequently resolved by either fission or a 1–2 min delay in IM fusion (Figures S3B and S3C). Therefore, uncoupling of OM fusion from IM fusion can occur under physiological conditions. Because nonproductive OM fusion intermediates are resolved by fission, the uncoupling rate can regulate the overall fusion rate of the matrix compartment.

Mitochondrial Encephalomyopathies Cause a Selective Defect in IM Fusion

Genetic defects in the OXPHOS machinery cause mitochondrial encephalomyopathies (DiMauro and Schon, 2003) that are asso-

ciated with defective mitochondrial ATP production, as well as muscular and nervous system pathology. Our findings above suggest that mitochondrial IM fusion rates may be depressed in these patients, especially under oxidative conditions. To test this hypothesis, we used isogenic cybrid cell lines harboring homoplasmic mtDNA mutations derived from patients with mitochondrial encephalomyopathy. The “ND1” cell line has severely reduced complex I activity, with no effect on complex II-driven respiration (Baracca et al., 2005). The “COX1” cell line is defective in complex IV and therefore has no measurable respiration via either complex I or complex II (Kwong et al., 2007). When grown in glucose-containing media, these two mutant cell lines have mitochondrial morphologies that are indistinguishable from that of wild-type cells (Figures 4A and 4B). Upon transfer to oxidative media, however, mutant cells are severely defective in mitochondrial elongation.

To quantify intrinsic mitochondrial fusion rates, we returned to the in vitro fusion assay. Mitochondria from ND1 and COX1 mutant cells exhibit a specific defect in IM fusion, with no reduction of OM fusion rates (Figure 4C). Importantly, the IM fusion defect of ND1 mitochondria, but not COX1 mitochondria, can be fully rescued by driving OXPHOS with complex II substrates.




Figure 5. Opa1 Processing at Site S2 Is Necessary for OXPHOS-Induced Fusion

(A) Inhibition of IM fusion events in vitro by o-phenanthroline. All reactions contain GTP. Suc, succinate; o-phe, o-phenanthroline. Error bars indicate standard deviations.

(B) Schematic of Opa1 mRNA splice forms 1 and 7, showing locations of the S1 and S2 cleavage sites. (C) Processing at the S1 (top two panels) and S2 (bottom two panels) sites of myc-Opa1 in vitro in response to respiratory conditions or ATP. Oxa1 levels are shown as a control. Processing to the short form of myc-Opa1 isoform 7ΔS1 (arrow) occurs in response to respiratory conditions.

(D) Processing at the Opa1 S2 site in vitro in response to ETC inhibition. Substrate (succinate, ADP) and drugs (antimycin A [ant A], oligomycin [oligo], and o-phenanthroline [o-phe]) were added as indicated.

In addition, both cell lines show normal levels of IM fusion driven by substrate level phosphorylation. Therefore, these disease cells have no intrinsic defect in the mitochondrial fusion machinery but have a specific defect in OXPHOS-driven mitochondrial fusion.

Proteolytic Cleavage of Opa1 Is Required for OXPHOS-Stimulated Fusion

To understand the molecular basis of OXPHOS-induced membrane fusion, we screened for pharmacologic agents that specifically inhibit this process. Numerous compounds—including kinase and phosphatase inhibitors, deacetylase inhibitors, and oxidizing and reducing agents—had no effect on inner or OM fusion (Figure S4A). The metalloprotease inhibitor o-phenanthroline, however, completely blocked IM fusion while leaving OM fusion intact (Figure 5A). This inhibitory effect was not due to an inhibition of respiration (Figure S4B) and could not be rescued by addition of ATP, suggesting the ATP may work upstream of the step inhibited by o-phenanthroline.

Intriguingly, Opa1, the central protein involved in IM fusion, is proteolytically processed by two metalloproteases, Oma1 and Yme1L. Oma1 processes l-Opa1 at the S1 cleavage site, whereas Yme1L processes l-Opa1 isoforms containing the S2 cleavage site (Figure 5B). Oma1 activity is inhibited by o-phenanthroline (Ehse et al., 2009; Kaser et al., 2003), and Yme1L belongs to a family of zinc-binding proteases (Langklotz et al., 2012) that should also be inhibited by metal chelation. These observations suggest the possibility that ongoing Opa1 cleavage is required for IM fusion. If this idea is correct, cleavage events should accumulate during the course of a productive fusion re-

action. We measured cleavage at S1 in mitochondria containing Myc-tagged Opa1 isoform 1 (which only contains the S1 site) and cleavage at S2 in mitochondria containing Opa1 isoform 7ΔS1 (which only contains the S2 site). Processing at S2 was stimulated by respiratory substrates or ATP (Figure 5C), conditions that promote IM fusion.

This stimulation was eliminated by the OXPHOS inhibitors antimycin A and oligomycin and by o-phenanthroline (Figure 5D). Thus, cleavage at S2 correlates with mitochondrial IM fusion in vitro. S1 cleavage was not stimulated by conditions permissive for IM fusion (Figure 5C). We observed similar stimulation of S2 (but not S1) cleavage in cells cultured under oxidative conditions (Figures S4C and S4D). Consistent with a role for S2 cleavage, cells containing mtDNA mutations in ND1 or COX1 show a selective reduction in S2 cleavage products (Figure S4E).

To further define the genetic requirements for OXPHOS-stimulated fusion, we examined cells lacking Oma1 or Yme1L. Like wild-type cells, Oma1 null MEFs respond to respiratory conditions by mitochondrial elongation (Figures S5A and S5B). In contrast, knockdown of Yme1L (Figures 6A, 6B, and S5C) prevents mitochondrial elongation induced by oxidative media, despite a normal mitochondrial respiration response (Figure S5D). This defect was rescued by expression of an RNAi-resistant form of Yme1L (Figure S5E). The inhibition of mitochondrial elongation is due to a failure to stimulate IM fusion under oxidative conditions, with no effect on OM fusion (Figures 6C, 6D, S5F, and S5G). IM fusion rates in glycolytic conditions were unaffected (Figure 6C). To further test the role of Yme1L, we designed siRNAs to selectively remove Opa1 mRNA splice forms that contain exon 5b, which encodes the S2 cleavage site. Two independent siRNAs against exon 5b blocked OXPHOS-stimulated mitochondrial elongation (Figures 6E, 6F, S5H, and S5I). In contrast, neither Yme1L nor Oma1 was singly required for mitochondrial elongation stimulated by starvation or cycloheximide treatment (Figure S5J).




Figure 6. Yme1L Is Necessary for OXPHOS-Induced Fusion

(A) Representative images of mitochondrial morphology in Yme1L-depleted MEFs at 24 hr after shifting to glycolytic (top) or oxidative (bottom) media. Mitochondria were visualized via staining for Tom20, a mitochondrial outer membrane protein. Scale bar, 5 μ m. (B) Quantification of mitochondrial morphology in control and Yme1L-depleted cells in glycolytic ("Glucose") versus oxidative ("Acetoacetate") media. (C) OM fusion rates (top) and IM fusion rates (bottom) measured by PA-GFP dilution in vivo under glycolytic conditions. Yme1L-knockdown cells are compared with control cells. (D) Same as (C), but under oxidative conditions. The p values were calculated for the slopes (pixel intensity versus time) using the Student's t test. *p < 0.01. (E) Representative images of mitochondrial morphology in exon 5b knock-down cells after shifting to glycolytic ("Glucose") or oxidative ("Acetoacetate") media for 24 hr. Mitochondria were visualized via staining for Tom20, a mitochondrial OM protein. Scale bar, 5 μ m. (F) Quantitation of mitochondrial morphology in control and exon 5b-depleted cells in glycolytic and oxidative media. All error bars indicate standard deviations.

Proteolytic Activation of Opa1 Is Sufficient to Trigger IM Fusion

Mitochondrial dysfunction is often associated with increased Opa1 cleavage (Duvezin-Caubet et al., 2006; Guillery et al., 2008b; Ishihara et al., 2006), leading to the idea that Opa1 cleavage inactivates mitochondrial fusion. Our data suggest the opposite hypothesis, that real-time proteolysis of Opa1 stimulates fusion. To expand this idea, we asked whether artificial cleavage of Opa1 is sufficient to trigger IM fusion. We used an engineered version of Opa1 with no endogenous cleavage sites (isoform 1 Δ S1) (Song et al., 2007) and introduced an artificial cleavage site recognized by the tobacco etch virus (TEV) protease at the position of the S2 site. This Opa1 variant was expressed in Opa1 null MEFs, and isolated mitochondria were analyzed in an in vitro fusion reaction. Mixed mitochondria were allowed to enter the initial stage of fusion, during which OM fusion occurred. We treated the mitochondria with a low concentration of digitonin that permeabilized the OM but left the IM intact (Figure S6A), and then added TEV protease to the reaction (Figure 7A). Strikingly, addition of digitonin and TEV were sufficient to promote IM fusion events, despite the absence of respiratory substrates and ATP (Figure 7B). Importantly, these events also bypassed the inhibitory effect of o-phenanthroline. Controls indicated that both digitonin and TEV were necessary to activate fusion, and no activation was observed with mitochondria containing an Opa1 variant lacking the TEV site (Figure 7B). Thus, proteolytic cleavage of Opa1 at S2 stimulates IM fusion.

These results prompted us to examine whether cleavage at S1 could similarly stimulate IM fusion. Opa1 splice forms that contain only an S1 site are sufficient to restore mitochondrial fusion to Opa1 null cells (Song et al., 2007). Mitochondria containing an Opa1 variant with a TEV site in place of S1 showed IM fusion triggered by digitonin and TEV (Figure 7C). Thus, activation of Opa1 is not limited to the S2 site; cleavage appears to be a general mechanism to stimulate IM fusion.

Treatment of cells or mitochondria with CCCP is known to inactivate mitochondrial fusion by inducing complete I-Opa1 cleavage at S1 by Oma1 (Ehse et al., 2009; Head et al., 2009; Ishihara et al., 2006). As a result, cleavage at S1 induced by CCCP treatment is generally thought to inactivate Opa1 function. In contrast, we wondered whether CCCP treatment might be able to paradoxically stimulate IM fusion of mitochondria stalled after OM fusion by respiratory inhibition. Wild-type mitochondria were allowed to undergo OM fusion in vitro, and then CCCP was added (Figure 7D). Remarkably, CCCP treatment stimulated IM fusion, removing the normal requirement for respiratory substrates (Figure 7E). Unlike OXPHOS-stimulated fusion, the CCCP-induced fusion is resistant to oligomycin treatment. It is,

however, abolished by o-phenanthroline (Figure 7E), consistent with the expectation that the CCCP effect is operating via cleavage of Opa1 (Figure S6B). To formally demonstrate the role of Oma1, we examined fusion in *Oma1* null mitochondria. These mitochondria show normal OXPHOS-stimulated IM fusion (as Yme1L is unaffected), but do not show CCCP-stimulated cleavage of Opa1 (Figure S6C) nor CCCP-stimulated fusion (Figure 7F). Taken together, these data indicate that Yme1L and Oma1 have profusion roles and that artificial cleavage of Opa1 can bypass the block to IM fusion caused by inhibition of OXPHOS.

DISCUSSION

Previous work defined a requirement for ATP in mitochondrial fusion (Hoppins et al., 2011; Meeusen et al., 2004; Schauss et al., 2010). In this study, we show that beyond having an energy requirement, mitochondrial fusion is sensitive to the OXPHOS activity of mitochondria. By tuning the levels of mitochondrial IM fusion to OXPHOS activity, cells may ensure that mitochondrial morphology and function match energy demands. Because OM fusion is insensitive to changes in mitochondrial metabolism, physiological uncoupling of OM and IM fusion can control overall fusion rates of the mitochondrial matrix. OXPHOS-stimulated IM fusion is disturbed in patients with mitochondrial encephalomyopathies. It should be noted that our in vitro assay with isolated mitochondria appears to primarily measure fusion associated with Yme1L-mediated cleavage of Opa1. In vivo, we expect Oma1-mediated cleavage to also be important.

Two distinct models have related Opa1 processing to mitochondrial fusion. First, both long and short isoforms are required for membrane fusion (DeVay et al., 2009; Herlan et al., 2003; Song et al., 2007). As a result, some proteolysis of Opa1 at S1 or S2 is required to produce an appropriate ratio of long and short isoforms. However, our results indicate that simply having a normal ratio of long and short isoforms is not sufficient for IM fusion, because mitochondria incubated acutely with o-phenanthroline show normal ratios of long and short Opa1 isoforms but have complete loss of IM fusion. Second, collapse of the mitochondrial IM potential by CCCP induces Oma1-dependent cleavage at S1 sites, complete loss of l-Opa1, and loss of mitochondrial fusion (Ehses et al., 2009; Head et al., 2009; Ishihara et al., 2006). Other conditions that cause mitochondrial dysfunction also promote excessive Opa1 cleavage, leading to the idea that Opa1 cleavage is an antifusion mechanism to prevent the merger of compromised mitochondria (Duvezin-Caubet et al., 2006). However, long-term depolarization by CCCP is a nonphysiological condition, and it is difficult to extrapolate the endogenous function of Oma1 cleavage from such experiments.

In contrast to these models, our data argue that proteolysis of Opa1 is a profusion event that operates at the time of fusion (Figure 7G). Although our study is focused on the bioenergetic regulation of IM fusion, it should be emphasized that Opa1 cleavage appears to be involved regardless of whether fusion is constitutive or regulated. The importance of real-time cleavage of Opa1 during the fusion reaction is strongly supported by our observation that artificial cleavage of l-Opa1 is sufficient to drive IM fusion. We imagine that Opa1 cleavage triggers structural rear-

rangements and/or stimulation of GTPase activity to promote the fusion reaction. This process ultimately results in a mixed population of long and short isoforms at steady state. Experiments with Mgm1, the yeast ortholog of Opa1, suggest that the short isoform has enhanced GTPase activity required for fusion (DeVay et al., 2009; Herlan et al., 2003). In a possible scenario, the cleavage of tethered l-Opa1 complexes may stimulate GTPase activity (via production of s-Opa1) and associated conformational changes to drive membrane fusion. Future experiments with cell-free fusion assays will be necessary to determine the molecular details of Opa1 activation. Although we find that Opa1 cleavage stimulates IM fusion, our results do not rule out the possibility that uncleaved Opa1 can mediate a basal level of fusion.

With Opa1 proteolytic cleavage associated with the fusion mechanism, control of the cleavage step provides an opportunity to regulate fusion. The interaction of two IM proteases with Opa1 probably enables its activity to be differentially regulated. With Yme1L (an ATP-dependent protease), OXPHOS or ATP stimulates cleavage of Opa1 at S2, thereby enhancing IM fusion in response to metabolic signals. Indeed, cleavage activity at S2 is lower in cells with pathogenic mtDNA mutations (Figure S4E). It is interesting to note that Yme1L has been reported to interact with subunits of complex V (Stiburek et al., 2012), raising the possibility that it may directly sense ATP generation by the respiratory chain. Opa1 can also be activated by Oma1-mediated cleavage at S1, although this mechanism is not engaged during OXPHOS-stimulated fusion in vitro. Pharmacologic treatment by CCCP is the best-documented activator of Oma1 (Ehses et al., 2009; Head et al., 2009). Interestingly, mitochondria are known to undergo transient depolarizations that correlate with fusion events (Santo-Domingo et al., 2013), and such events may serve to stimulate Oma1 activity under basal conditions.

EXPERIMENTAL PROCEDURES

Reagents

Antibodies to the following proteins were used: Drp1 (BD Biosciences), Drp1 S637-PO₄ (Cell Signaling), Actin (Millipore), Fis1 (Alexis Corps), Mff (Sigma-Aldrich), Mfn1 (Chen et al., 2003), Mfn2 (Sigma), Opa1 (in house monoclonal), ClpP (Proteintech Group), Oxa1 (Proteintech Group), Tom20 (Santa Cruz BioTech), Hsp60 (Santa Cruz BioTech), Yme1L (Proteintech Group), and Myc (Covance). Oligomycin (Sigma-Aldrich), antimycin A (Sigma-Aldrich), atpenin A5 (Santa Cruz BioTech), CCCP (Sigma-Aldrich), and atractyloside (Sigma-Aldrich) were used at 1 μ M. Concentrations of other compounds: rotenone (Sigma-Aldrich), 200 nM; KCN (Sigma-Aldrich), 1 mM; o-phenanthroline (Sigma-Aldrich), 0.5 mM; aspartate, 1 mM; ADP (Sigma-Aldrich), 200 μ M; β -NADH (Sigma-Aldrich), 2 mM. Unless otherwise indicated, substrates (pyruvate, malate, succinate, α -ketoglutarate) were used at 5 mM.

Cell Culture

MEFs were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and penicillin/streptomycin at 37°C and 5% CO₂. 143B (human osteosarcoma) cells were similarly maintained, except with 5% FBS and the addition of 50 μ g/ml uridine. *Opa1* null and *Oma1* null MEFs were described previously (Quirós et al., 2012; Song et al., 2007). Cells with homoplasmic mtDNA mutations are cybrids from the fusion of enucleated patient cells with 143B rho⁰ cells (lacking mtDNA) (Baracca et al., 2005; Kwong et al., 2007). ND1 cells have a G \rightarrow A mutation at nucleotide 3460 in the ND1 subunit of complex I. COXI cells have a premature stop codon at nucleotide 6390 in the cytochrome c oxidase subunit I gene of complex IV. Stable cell lines with labeled




Figure 7. Induced Proteolytic Processing of Opa1 Promotes Inner Membrane Fusion

(A) Schematic of the in vitro fusion experiment in (B) and (C). o-phenanthroline is present throughout, and digitonin and TEV protease are added after OM fusion. (B) Induction of IM fusion by engineered cleavage at S2. OM and IM fusion events in mitochondria containing Opa1 lacking a TEV site (1ΔS1) or containing a TEV site at the S2 position (1ΔS1 + TEV@S2). In the latter, S2 cleavage was controlled by addition of digitonin and TEV. (C) Induction of IM fusion by engineered cleavage at S1. The experiment is similar to (B), but using an Opa1 isoform containing a TEV site at the S1 position. Same color scheme as (B).

(legend continued on next page)

Seahorse TC plate. The plate was spun at 2,000 g, 4°C for 20 min to pellet mitochondria. Additional isolation buffer was added to a final volume of 200 μ l. The plate was equilibrated for 10 min at 37°C prior to measuring oxygen consumption. Oxygen levels were measured over 5 min periods.

Membrane potential measurements on isolated mitochondria were performed by visualization of TMRM fluorescence. Mitochondria from the indicated condition were loaded with TMRM (10 nM) for 10 min at room temperature and then washed into isolation buffer containing 2 nM TMRM. Samples were imaged by fluorescence microscopy using identical imaging parameters. The average fluorescence for each mitochondrion (after subtraction of background fluorescence) was calculated. More than 100 mitochondria were quantified per sample, and experiments were performed in triplicate.

SUPPLEMENTAL INFORMATION

Supplemental Information includes six figures and can be found with this article online at <http://dx.doi.org/10.1016/j.cmet.2014.03.011>.

ACKNOWLEDGMENTS

This work was supported by grant GM062967 from the National Institutes of Health. P.M. was supported by a fellowship from the Jane Coffin Childs Memorial Fund for Medical Research. We thank Dr. Andrea Martinuzzi for construction of the ND1 cybrid, Dr. Carlos López-Otín for providing *Oma1*-null cells, and members of the Chan lab for helpful discussions and comments on the manuscript.

Received: January 29, 2013

Revised: December 3, 2013

Accepted: January 27, 2014

Published: April 1, 2014

REFERENCES

- Baracca, A., Solaini, G., Sgarbi, G., Lenaz, G., Baruzzi, A., Schapira, A.H., Martinuzzi, A., and Carelli, V. (2005). Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids. *Arch. Neurol.* 62, 730–736.
- Cereghetti, G.M., Stangherlin, A., Martins de Brito, O., Chang, C.R., Blackstone, C., Bernardi, P., and Scorrano, L. (2008). Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. *Proc. Natl. Acad. Sci. USA* 105, 15803–15808.
- Chan, D.C. (2012). Fusion and fission: interlinked processes critical for mitochondrial health. *Annu. Rev. Genet.* 46, 265–287.
- Chance, B., and Williams, G.R. (1955). Respiratory enzymes in oxidative phosphorylation. III. The steady state. *J. Biol. Chem.* 217, 409–427.
- Chen, H., Detmer, S.A., Ewald, A.J., Griffin, E.E., Fraser, S.E., and Chan, D.C. (2003). Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. *J. Cell Biol.* 160, 189–200.
- Cribbs, J.T., and Strack, S. (2007). Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. *EMBO Rep.* 8, 939–944.
- Delettre, C., Griffoin, J.M., Kaplan, J., Dollfus, H., Lorenz, B., Faivre, L., Lenaers, G., Belenguer, P., and Hamel, C.P. (2001). Mutation spectrum and splicing variants in the OPA1 gene. *Hum. Genet.* 109, 584–591.
- DeVay, R.M., Dominguez-Ramirez, L., Lackner, L.L., Hoppins, S., Stahlberg, H., and Nunnari, J. (2009). Coassembly of Mgm1 isoforms requires cardiolipin and mediates mitochondrial inner membrane fusion. *J. Cell Biol.* 186, 793–803.
- DiMauro, S., and Schon, E.A. (2003). Mitochondrial respiratory-chain diseases. *N. Engl. J. Med.* 348, 2656–2668.
- Duvezin-Caubet, S., Jagasia, R., Wagoner, J., Hofmann, S., Trifunovic, A., Hansson, A., Chomyn, A., Bauer, M.F., Attardi, G., Larsson, N.G., et al. (2006). Proteolytic processing of OPA1 links mitochondrial dysfunction to alterations in mitochondrial morphology. *J. Biol. Chem.* 281, 37972–37979.
- Ehres, S., Raschke, I., Mancuso, G., Bernacchia, A., Geimer, S., Tondera, D., Martinou, J.C., Westermann, B., Rugari, E.I., and Langer, T. (2009). Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1. *J. Cell Biol.* 187, 1023–1036.
- Griparic, L., Kanazawa, T., and van der Bliek, A.M. (2007). Regulation of the mitochondrial dynamin-like protein Opa1 by proteolytic cleavage. *J. Cell Biol.* 178, 757–764.
- Guillery, O., Malka, F., Frachon, P., Milea, D., Rojo, M., and Lombès, A. (2008a). Modulation of mitochondrial morphology by bioenergetics defects in primary human fibroblasts. *Neuromuscul. Disord.* 18, 319–330.
- Guillery, O., Malka, F., Landes, T., Guillou, E., Blackstone, C., Lombès, A., Belenguer, P., Arnoult, D., and Rojo, M. (2008b). Metalloprotease-mediated OPA1 processing is modulated by the mitochondrial membrane potential. *Biol. Cell* 100, 315–325.
- Handran, S.D., Werth, J.L., DeVivo, D.C., and Rothman, S.M. (1997). Mitochondrial morphology and intracellular calcium homeostasis in cytochrome oxidase-deficient human fibroblasts. *Neurobiol. Dis.* 3, 287–298.
- Head, B., Griparic, L., Amiri, M., Gandre-Babbe, S., and van der Bliek, A.M. (2009). Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. *J. Cell Biol.* 187, 959–966.
- Herlan, M., Vogel, F., Bornhove, C., Neupert, W., and Reichert, A.S. (2003). Processing of Mgm1 by the rhomboid-type protease Pcp1 is required for maintenance of mitochondrial morphology and of mitochondrial DNA. *J. Biol. Chem.* 278, 27781–27788.
- Hermann, G.J., Thatcher, J.W., Mills, J.P., Hales, K.G., Fuller, M.T., Nunnari, J., and Shaw, J.M. (1998). Mitochondrial fusion in yeast requires the transmembrane GTPase Fzo1p. *J. Cell Biol.* 143, 359–373.
- Hoppins, S., Edlich, F., Cleland, M.M., Banerjee, S., McCaffery, J.M., Youle, R.J., and Nunnari, J. (2011). The soluble form of Bax regulates mitochondrial fusion via MFN2 homotypic complexes. *Mol. Cell* 41, 150–160.
- Huckriede, A., Heikema, A., Sjollem, K., Briones, P., and Agsteribbe, E. (1995). Morphology of the mitochondria in heat shock protein 60 deficient fibroblasts from mitochondrial myopathy patients. Effects of stress conditions. *Virchows Arch.* 427, 159–165.
- Ishihara, N., Fujita, Y., Oka, T., and Mihara, K. (2006). Regulation of mitochondrial morphology through proteolytic cleavage of OPA1. *EMBO J.* 25, 2966–2977.
- Karbowski, M., Arnoult, D., Chen, H., Chan, D.C., Smith, C.L., and Youle, R.J. (2004). Quantitation of mitochondrial dynamics by photolabeling of individual organelles shows that mitochondrial fusion is blocked during the Bax activation phase of apoptosis. *J. Cell Biol.* 164, 493–499.
- Kaser, M., Kambacheld, M., Kisters-Woike, B., and Langer, T. (2003). Oma1, a novel membrane-bound metalloprotease with activities overlapping with the m-AAA protease. *J. Biol. Chem.* 278, 46414–46423.
- Koopman, W.J., Visch, H.J., Verkaar, S., van den Heuvel, L.W., Smeitink, J.A., and Willems, P.H. (2005). Mitochondrial network complexity and pathological decrease in complex I activity are tightly correlated in isolated human complex I deficiency. *Am. J. Physiol. Cell Physiol.* 289, C881–C890.
- Kwong, J.Q., Henning, M.S., Starkov, A.A., and Manfredi, G. (2007). The mitochondrial respiratory chain is a modulator of apoptosis. *J. Cell Biol.* 179, 1163–1177.
- Langklotz, S., Baumann, U., and Narberhaus, F. (2012). Structure and function of the bacterial AAA protease FtsH. *Biochim. Biophys. Acta* 1823, 40–48.
- Legros, F., Lombès, A., Frachon, P., and Rojo, M. (2002). Mitochondrial fusion in human cells is efficient, requires the inner membrane potential, and is mediated by mitofusins. *Mol. Biol. Cell* 13, 4343–4354.
- Malka, F., Guillery, O., Cifuentes-Diaz, C., Guillou, E., Belenguer, P., Lombès, A., and Rojo, M. (2005). Separate fusion of outer and inner mitochondrial membranes. *EMBO Rep.* 6, 853–859.
- Meeusen, S., McCaffery, J.M., and Nunnari, J. (2004). Mitochondrial fusion intermediates revealed in vitro. *Science* 305, 1747–1752.
- Meeusen, S., DeVay, R., Block, J., Cassidy-Stone, A., Wayson, S., McCaffery, J.M., and Nunnari, J. (2006). Mitochondrial inner-membrane fusion and crista maintenance requires the dynamin-related GTPase Mgm1. *Cell* 127, 383–395.
- Quirós, P.M., Ramsay, A.J., Sala, D., Fernández-Vizcarra, E., Rodríguez, F., Peinado, J.R., Fernández-García, M.S., Vega, J.A., Enríquez, J.A., Zorzano, A.

- A., and López-Otín, C. (2012). Loss of mitochondrial protease OMA1 alters processing of the GTPase OPA1 and causes obesity and defective thermogenesis in mice. *EMBO J.* 31, 2117–2133.
- Rogers, G.W., Brand, M.D., Petrosyan, S., Ashok, D., Elorza, A.A., Ferrick, D.A., and Murphy, A.N. (2011). High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria. *PLoS ONE* 6, e21746.
- Rossignol, R., Gilkerson, R., Aggeler, R., Yamagata, K., Remington, S.J., and Capaldi, R.A. (2004). Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. *Cancer Res.* 64, 985–993.
- Santo-Domingo, J., Giacomello, M., Poburko, D., Scorrano, L., and Demareux, N. (2013). OPA1 promotes pH flashes that spread between contiguous mitochondria without matrix protein exchange. *EMBO J.* 32, 1927–1940.
- Sauvanet, C., Duvezin-Caubet, S., di Rago, J.P., and Rojo, M. (2010). Energetic requirements and bioenergetic modulation of mitochondrial morphology and dynamics. *Semin. Cell Dev. Biol.* 21, 558–565.
- Sauvanet, C., Duvezin-Caubet, S., Salin, B., David, C., Massoni-Laporte, A., di Rago, J.P., and Rojo, M. (2012). Mitochondrial DNA mutations provoke dominant inhibition of mitochondrial inner membrane fusion. *PLoS ONE* 7, e49639.
- Schauss, A.C., Huang, H., Choi, S.Y., Xu, L., Soubeyrand, S., Bilodeau, P., Zunino, R., Rippstein, P., Frohman, M.A., and McBride, H.M. (2010). A novel cell-free mitochondrial fusion assay amenable for high-throughput screenings of fusion modulators. *BMC Biol.* 8, 100.
- Song, Z., Chen, H., Fiket, M., Alexander, C., and Chan, D.C. (2007). OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L. *J. Cell Biol.* 178, 749–755.
- Song, Z., Ghochani, M., McCaffery, J.M., Frey, T.G., and Chan, D.C. (2009). Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. *Mol. Biol. Cell* 20, 3525–3532.
- Stiburek, L., Cesnekova, J., Kostkova, O., Fornuskova, D., Vinsova, K., Wenchich, L., Houstek, J., and Zeman, J. (2012). YME1L controls the accumulation of respiratory chain subunits and is required for apoptotic resistance, cristae morphogenesis, and cell proliferation. *Mol. Biol. Cell* 23, 1010–1023.
- Westermann, B. (2010). Mitochondrial fusion and fission in cell life and death. *Nat. Rev. Mol. Cell Biol.* 11, 872–884.
- Youle, R.J., and van der Bliek, A.M. (2012). Mitochondrial fission, fusion, and stress. *Science* 337, 1062–1065.